PDX Portal

Model Details

Patient Information for Model: HCI-005

Model Contact

Model: HCI-005
Model Contact: Alana Welm
Institution: HCI Breast PDX Program
Email: Alana.Welm@hci.utah.edu

Patient Information

Clinical Timeline

Color Keys:

Positive

Negative

N/A

Clinical Information at Collection

Clinical Biomarkers/Mutations at Collection

Pathology Information at Collection

Model Information for Model: HCI-005

Model Details - Initial Implantation of Patient Tissue

Biomarkers & Mutations

Model Details - Acceptable Conditions for Passaging

Mutations (Cancer Gene Census List)

Mutation data is currently not available.

CNV

Histology Information for Model: HCI-005

There are no histology images for this model.

Metastasis Information for Model: HCI-005

Patient

PDX

Abdomen

Adrenal gland

Bone

Bones

Brain

CTC

Chest

Chest wall

Contralateral Breast

Dura

Fallopian Tubes

Head

Kidney

Liver

Lung

Lymph node

Lymph nodes

Neck

Ovary

Pancreas

Pericardium

Peritoneal cavity

Peritoneum

Pleura

Pleural effusion

Shoulder

Skin

Spine

Spleen

Thoracic Spine

Thymus

Patient Treatment Information for Model: HCI-005

Event Id	Treatment	Treatment Setting	Age at Start	Age at End	Duration	Clinical Response
11	Radiation Therapy	Neoadjuvant	45.0	45.08	29 days
12	Doxorubicin, Cyclophosphamide	Neoadjuvant	45.08	45.16	29 days	Progressive disease
13	Tamoxifen	Neoadjuvant	45.2	49.08	1416 days	Progressive disease
20	Radiation Therapy	Neoadjuvant	49.08	49.16	29 days
21	Letrozole	Neoadjuvant	49.08	49.91	303 days	Progressive disease
22	Zolendronic Acid	Neoadjuvant	49.16	54.16	1825 days	Progressive disease
23	Fulvestrant	Neoadjuvant	49.91	50.08	62 days	Progressive disease
25	Capecitabine	Neoadjuvant	50.08	51.75	610 days	Progressive disease
26	Radiation Therapy	Neoadjuvant	51.0	51.08	29 days
27	Aromasin	Neoadjuvant	51.67	51.75	29 days	Progressive disease
28	Trastuzumab	Neoadjuvant	51.77	51.91	51 days	Progressive disease
29	Vinorebline	Neoadjuvant	51.85	51.99	51 days	Progressive disease
32	Paclitaxel	Neoadjuvant	52.0	52.25	91 days	Progressive disease
37	Taxotere	Adjuvant	52.25	52.33	29 days	Progressive disease
41	Liposomal Doxorubicin	Adjuvant	52.75	53.5	274 days	Progressive disease